Table 2 Changes in the studied groups (mean ± SD)

Bilirubin

Treated

1.88 ± 1.05

1.92 ± 1.22

1.89 ± 1.36

1.82 ± 1.3

2.06 ± 1.26

Control

2.51 ± 0.94

2.87 ± 1.5

3.3 ± 2.14

4.02 ± 3.29

4.24 ± 2.48

P value

0.4

0.025

0.006

0.001

0.002

Albumin

Treated

2.59 ± 0.28

3.03 ± 0.44

3.05 ± 0.41

2.99 ± 0.26

3.06 ± 0.36

Control

2.62 ± 0.37

2.63 ± 0.27

2.63 ± 0.14

2.63 ± 0.3

2.43 ± 0.36

P value

0.77

0.001

0.000

0.000

0.000

PC (%)

Treated

55.34 ± 9.06

61.15 ± 15.99

62.89 ± 18.2

59.45 ± 15.23

57.59 ± 14.68

Control

52.85 ± 10.16

53.65 ± 11.01

49.35 ± 10.35

50.45 ± 11.42

45.03 ± 10.92

P value

0.41

0.92

0.007

0.041

0.029

INR

Treated

1.53 ± 0.19

1.47 ± 0.29

1.44 ± 0.28

1.47 ± 0.23

1.52 ± 0.36

Control

1.66 ± 0.33

1.62 ± 0.39

1.76 ± 0.4

1.73 ± 0.4

1.84 ± 0.39

P value

0.12

0.2

0.007

0.31

0.017

ASTfold

Treated

2.29 ± 1.51

2.03 ± 0.79

1.83 ± 1.13

1.97 ± 1.09

2.14 ± 0.88

Control

1.81 ± 0.84

1.68 ± 0.65

1.75 ± 0.71

1.66 ± 0.73

1.64 ± 0.69

P value

0.46

0.14

0.85

0.48

0.156

ALT fold

Treated

1.35 ± 0.87

1.17 ± 0.71

1.1 ± 0.58

1.06 ± 0.64

1.27 ± 0.3

Control

0.9 ± 0.52

0.87 ± 0.41

0.81 ± 0.46

0.81 ± 0.54

1.09 ± 1.47

P value

0.55

0.13

0.172

0.093

0.029